AMAG Pharmaceuticals Inc (AMAG.OQ)
24.85USD
18 May 2018
$0.20 (+0.81%)
$24.65
$24.75
$24.90
$24.55
26,803
260,715
$24.90
$11.93
About
Overall
| Beta: | 0.91 |
| Market Cap(Mil.): | $661.66 |
| Shares Outstanding(Mil.): | 35.29 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| AMAG.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.95 | 32.75 |
| EPS (TTM): | -1.39 | -- | -- |
| ROI: | -2.17 | 14.84 | 14.38 |
| ROE: | -4.83 | 16.34 | 16.07 |
BRIEF-AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59
* AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RAISES FULL YEAR FINANCIAL GUIDANCE
BRIEF-AMAG Pharmaceuticals Appoints J. Alan Butcher As Executive Vice President
* AMAG PHARMACEUTICALS APPOINTS J. ALAN BUTCHER AS EXECUTIVE VICE PRESIDENT AND CHIEF BUSINESS OFFICER Source text for Eikon: Further company coverage:
BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide
* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:
BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal
* AMAG PHARMACEUTICALS - CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION
BRIEF-AMAG Reports Q4 Earnings Of $0.10 Per Share
* TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION
BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector
* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN
BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme
* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEME® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:
BRIEF-AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln
* AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE
UPDATE 1-Around 6,000 Swiss VW owners seek damages in emissions scandal
* VW says 98 percent of affected vehicles already fixed (Adds VW reaction)
BRIEF-New Patent Issued To Amag Pharmaceuticals Entitled "Methods Of Reducing Risk Of Preterm Birth"
* NEW PATENT ISSUED TO AMAG PHARMACEUTICALS ENTITLED "METHODS OF REDUCING RISK OF PRETERM BIRTH" Source text for Eikon: Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Takeda Pharmaceutical Co Ltd (4502.T) | ¥4,690 | -49.00 |
| Sanofi SA (SASY.PA) | €66.44 | +0.32 |
| Fresenius Medical Care AG & Co. KGaA (FMEG.DE) | €86.54 | -1.96 |
| Vifor Pharma AG (VIFN.S) | -- | -- |
Estimates